In the BioHarmony Drug Report Database
Varenicline
Chantix, Champix (varenicline) is a small molecule pharmaceutical. Varenicline was first approved as Chantix on 2006-09-25. It has been approved in Europe to treat tobacco use cessation. The pharmaceutical is active against neuronal acetylcholine receptor subunit alpha-4. In addition, it is known to target neuronal acetylcholine receptor subunit alpha-3.
Trade Name
|
Champix |
|---|---|
Common Name
|
varenicline |
ChEMBL ID
|
CHEMBL1396 |
Indication
|
tobacco use cessation |
Drug Class
|
Nicotinic acetylcholine receptor partial agonists/agonists |
Image (chem structure or protein)